$MAIA

MAIA Biotechnology (NYSE American: MAIA) reported initial Phase 2 THIO-101 Part C data in third-line advanced NSCLC. Ateganosine followed by cemiplimab (Libtayo) produced a 90.5% disease control rate (19/21) in 3L patients, compared with 25-35% for standard chemotherapy. MAIA said safety is acceptable and enrollment is completed internationally.

MAIA Biotechnology (NYSE American: MAIA) said it completed international enrollment in Part C of its Phase 2 THIO-101 expansion trial for ateganosine in third-line non-small cell lung cancer after resistance to checkpoint inhibitors and chemotherapy. The company enrolled 41 patients in Taiwan, Turkey, Poland, Hungary, Romania and Georgia; U.S. screening continues at three sites. MAIA previously reported median survival of 17.8 months in Parts A/B and Fast Track designation for ateganosine.

MAIA Biotechnology (NYSE American: MAIA) said the Winship Cancer Institute of Emory University has been activated and is enrolling patients in the third U.S. site of its Phase 2 THIO-101 expansion trial. The study evaluates ateganosine as third-line treatment for non-small cell lung cancer, followed by cemiplimab. Principal investigator Ticiana Leal, M.D. cited Georgia lung cancer need.

MAIA Biotechnology said its founder and CEO Vlad Vitoc and director Stan V. Smith increased their holdings via open market buys on June 6, 2026. Vitoc bought about 72,700 shares at an average $1.3877; Smith bought about 75,000 shares at an average $1.336. The company said officers and directors hold 20.46% of MAIA.

Vitoc Vlad (Chief Executive Officer) purchased 72,700 shares of MAIA Biotechnology, Inc. (MAIA) at $1.39 ($0.10M total) on 2026-06-01.

Smith Stan purchased 75,000 indirectly-held shares of MAIA Biotechnology, Inc. (MAIA) at $1.34 ($0.10M total) on 2026-06-01.

Gryaznov Sergei (Chief Scientific Officer) purchased 2,000 shares of MAIA Biotechnology, Inc. (MAIA) at $1.34 on 2026-06-01.

MAIA Biotechnology, Inc. announced a private placement bringing in approximately $1.51 million. The company will sell 1,233,488 shares of common stock at $1.224 per share, with each share including a warrant to purchase another share at $1.36. The proceeds will fund Step 1 of Part C of the Phase II trial THIO -101 and general working capital.

First five patients in Part C ( expansion ) of THIO-101 Phase 2 clinical trial enrolled in Taiwan and Turkey ...

CHICAGO, Oct. 23, 2025 ( GLOBE NEWSWIRE ) -- MAIA Biotechnology, Inc. ( NYSE American: MAIA ) ( "MAIA", the "Company" ) , a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced highlights from a recent presentation at the European ...